Opening book details…
Can I read Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis on EtoBox?
Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis by Sean A. Woolen; Prasad R. Shankar; Joel J. Gagnier; Mark P. MacEachern; Lisa Singer; Matthew S. Davenport is a Medicine article available to read on EtoBox.
What is Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis about?
## Importance: Risk of nephrogenic systemic fibrosis (nsf) to individual patients with stage 4 or 5 chronic kidney disease (ckd; defined as estimated glomerular filtration rate of <30 ml/min/1.73 m2) who receive a group ii gadolinium-based contrast agent (gbca) is not well understood or summarized in the literature. ## Objective: To assess the pooled risk of nsf in patients with stage 4 or 5 ckd receiving a group ii gbca. ## Data sources: A health sciences informationist searched the ovid (medline and medline epub ahead of print, in-process & other non-indexed citation, and daily and versions), embase, cochrane central register of controlled trials, web of science, and open grey databases from inception to january 29, 2019, yielding 2700 citations. ## Study selection: Citations were screened for inclusion in a multistep process. agreement for final cohort inclusion was determined by 2 blinded screeners using cohen κ. inclusion criteria consisted of stage 4 or 5 ckd with or without dialysis, administration of an unconfounded american college of radiology classification group ii gbca (gadobenate dimeglumine, gadobutrol, gadoterate meglumine, or gadoteridol), and incident nsf as an ou
Who reads Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Sean A. Woolen; Prasad R. Shankar; Joel J. Gagnier; Mark P. MacEachern; Lisa Singer; Matthew S. Davenport
- Publisher
- American Medical Association (AMA)
- Published
- 2019
- Language
- EN
- Field
- Medicine (Health Sciences)